Ironwood Pharma

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ironwood Pharma excels in Q4 with LINZESS growth and pipeline advancements

Ironwood Pharmaceuticals delivered a strong performance in Q4 2022, driven by LINZESS's growth and pipeline progress. Strategic priorities emphasize profitability and portfolio strength, while challenges around pricing and data release plans require attention. Opportunities exist in expanding LINZESS sales, pediatric indications, and pipeline investments for future growth.

Ironwood Pharma excels in Q1 with LINZESS driving growth

Ironwood Pharma's Q1 2023 showcased strong LINZESS demand, revenue growth, and profitability. The company's strategic focus on LINZESS and innovative pipeline positions it well for sustained success amidst market challenges and growth opportunities.

Ironwood Pharma reports strong Q2 performance and growth opportunities

Ironwood Pharmaceuticals showcased strong performance in Q2 2023, driven by robust U.S. net sales and strategic acquisitions.
While facing challenges in managing the impact of the VectivBio acquisition on EBITDA, the company is well-positioned for growth.
Opportunities lie in expanding LINZESS sales, advancing pipeline candidates like apraglutide, and diversifying into new indications.
Overall, Ironwood's focus on maximizing key products, pipeline advancement, and financial management sets a positive trajectory.

Ironwood Pharma reports strong Q3 performance amidst strategic acquisitions

Ironwood Pharmaceuticals showcased strong performance driven by LINZESS and the acquisition of VectivBio for apraglutide.
While facing challenges in managing financial losses and addressing competitive pressures, Ironwood remains focused on growth opportunities and product development.
Opportunities lie in upcoming Phase III data for apraglutide, pediatric market expansion for LINZESS, and exploring new patient subgroups for apraglutide.

Ironwood Pharma excels in Q4, eyes pediatric market growth

Ironwood Pharmaceuticals showcased robust financial performance, strategic acquisitions, and a focus on pipeline assets during their Q4 2023 earnings call. While facing challenges in defining efficacy and pricing strategies, the company remains optimistic about growth opportunities in the GI market, particularly in the pediatric segment.

Ironwood Pharma reports Q1 growth, prepares for apraglutide launch

Ironwood Pharma's Q1 2024 performance reflects growth in LINZESS prescription volume and positive developments in its pipeline, despite challenges in net sales and guidance adjustments. The company's strategic focus on maximizing LINZESS and preparing for apraglutide's launch presents opportunities for future growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Ironwood (IRWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Ironwood (IRWD) Could Beat Earnings Estimates Again

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced the appointment of John Minardo as senior vice president, chief legal officer. Mr. Minardo will become a member of Ironwood's Leadership Team and oversee the company's Corporate Legal, Compliance and IP teams. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, “John's deep legal experience and proven track record, in particular his e

Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth

Bausch Health Companies Inc

Regeneron Pharmaceuticals

Zoetis

We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.

4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2

Ironwood (IRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Ironwood (IRWD) Hits 52-Week High, Can the Run Continue?

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 5, 2021. Individuals interested in participating in the call should dial (833) 350-1432 (U.S. and Canada) or (647) 689-6932 (international) using conference ID number and event passcode 2598317. To access the webcast, please visit the Investors section of Ironwood's website at www.iro

Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call

ACNB

Agree Realty

Asana

PennyMac Financial Services

Transocean

Tracking stocks insiders are buying is always helpful. Tips for beating the market tend to come and go quickly, but this one has held up.

7 Stocks That Insiders Are Snapping Up Right Now

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The American College of Gastroenterology – published full results from the company's Phase IIIb clinical trial evaluating LINZESS® (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C). The results, which can be viewed here, demonstr

Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, 2021, as permanent chief executive officer. Mr. McCourt has also been appointed to serve on Ironwood's Board. With the appointment of Mr. McCourt, the Board is now comprised of 11 directors. Ironwood also announced that Gina Consylman plans to step

Ironwood Pharmaceuticals Announces Leadership Updates

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva's abbreviated new drug application (ANDA) seeking approval to market a generic version of 72 mcg LINZESS® (linaclotide) prior to the expiration of the companies' applicable patents. With this agreement, the companies have settled with the filers of all known ANDAs to dat

Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, presented new findings at the Digestive Disease Week® (DDW) 2021 virtual meeting from a survey highlighting disease burden and care-seeking behavior among adult patients with irritable bowel syndrome with constipation (IBS-C) during the COVID-19 pandemic. The poster presentation, titled Disease Burden and Care-Seeking Behavior for IBS-C Patients in the United States in the Era of COVID-19 (p

More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present seven posters – four of which have been named posters of distinction – during the Digestive Disease Week® (DDW) 2021 virtual meeting being held from May 21 through May 23, 2021. Two posters of distinction will discuss the impact of linaclotide on visceral hypersensitivity. Ironwood is focused on advancing the science and unde

Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021

Ironwood Pharmaceuticals (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

Moving Average Crossover Alert: Ironwood Pharmaceuticals (IRWD)

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Thomas McCourt on Q1 2021 Results - Earnings Call Transcript

Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. However, outlook for 2021 misses market expectations.

Ironwood's (IRWD) Q1 Earnings Beat, 2021 Guidance Muted

Ironwood (IRWD) delivered earnings and revenue surprises of 9.09% and 3.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Q1 Earnings and Revenues Beat Estimates

Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 500.00% over the past year to $0.24, which beat the estimate of $0.21.

Recap: Ironwood Pharmaceuticals Q1 Earnings

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals Reports First Quarter 2021 Results

Ironwood Pharmaceuticals Reports First Quarter 2021 Results

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 6, 2021. Individuals interested in participating in the call should dial (833) 350-1432 (U.S. and Canada) or (647) 689-6932 (international) using conference ID number and event passcode 8067476. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoo

Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Ironwood (IRWD) Up 20.4% Since Last Earnings Report: Can It Continue?

Microsoft

News Corp

Snowflake

Walmart

Archer-Daniels-Midland Company

Broadcom

Cerner

Dropbox

Fastly

Parker-Hannifin

Carrols Restaurant Group

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. A media mogul was among the insiders making purchases this week.

Last Week's Notable Insider Buys: News Corp, Microsoft, Snowflake, Walmart And More

Danaher

DTE Energy

Nautilus

Primo Water

Sensei Biotherapeutics

LendingTree

There are many reasons an insider might sell. But there is only one reason for insider buying; insiders think the stock will trade higher.

7 Stocks With Significant Insider Buying

Editas Medicine

Exxon Mobil

Mack-Cali Realty

Discovery

Enterprise Products Partners

Teledyne Technologies

Wayfair

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. A pair of chief executives and an executive board chair were among the insiders making purchases this week.

The Past Week's Most Notable Insider Buys: Editas, Exxon Mobil, Wayfare And More

Coherus BioSciences

Supernus Pharmaceuticals

Their recent struggles may soon give way to rising market interest and more lucrative returns.

News for Ironwood Pharma Stock (IRWD)